Stock Movers: Mondelez, Starbucks, Novo Nordisk (Podcast)

Mondelez (MDLZ) reported better-than-expected second-quarter earnings and sales, reaffirming its annual outlook on strong pricing execution and global growth. Conversely, Starbucks (SBUX) posted a larger-than-anticipated decline in fiscal third-quarter sales and profit, signaling its turnaround plan has yet to materialize, despite a modest after-hours share gain. Concurrently, Novo Nordisk (NOVOB DC) appointed a new CEO, Maziar Mike Doustdar, following a profit warning that erased $93 billion from its market value due to slumping weight-loss drug sales and heightened competition from Eli Lilly.

Analysis

The market is digesting a mixed set of corporate earnings and strategic updates, highlighting divergent performances across consumer and healthcare sectors. Mondelez (MDLZ) demonstrated strong execution, posting second-quarter results that surpassed analyst estimates with adjusted EPS of 73 cents against a 68-cent consensus and sales of $8.98 billion versus an expected $8.84 billion. The company's ability to reiterate its annual outlook, driven by robust pricing in its chocolate business and broad geographic growth, signals operational resilience in a challenging environment. In sharp contrast, Starbucks (SBUX) revealed that its turnaround strategy has yet to deliver, reporting a fiscal third-quarter comparable sales decline of 2%, which was steeper than the 1.5% drop anticipated. The earnings miss was more pronounced, with EPS of 50 cents falling well short of the 65-cent forecast, underscoring the difficulties in reviving growth despite initiatives to improve service and store environments. The most significant development came from Novo Nordisk (NOVOB DC), which announced a new CEO, Maziar Mike Doustdar, in the wake of a severe profit warning that erased $93 billion from its market value. The company dramatically slashed its full-year forecast, cutting expected sales growth from a high of 21% to a range of 8-14% and operating profit growth from up to 24% to 10-16%, citing slumping weight-loss drug sales and intensified competition from Eli Lilly & Co.

Key Decisions for Investors

• Investors may view Mondelez's earnings beat and reaffirmed guidance as a confirmation of its pricing power and defensive positioning, justifying confidence in its ability to navigate consumer spending pressures.
• For Starbucks, the significant earnings and sales miss introduces heightened execution risk, and despite a minor after-hours share increase, it is prudent to await tangible evidence of the turnaround plan's success before increasing exposure.
• The severe guidance cut and CEO change at Novo Nordisk signal a fundamental deterioration in its competitive standing against Eli Lilly, warranting extreme caution and a reassessment of its long-term growth trajectory in the obesity drug market.